Pomalidomide

Generic Name: Pomalidomide

Brand Names: Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₁₁N_₃O_₄

CAS Number: 19171-19-8

Unique Ingredient Identifier: D2UX06XLB5

Background: Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Indication: Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.

Associated Conditions: Kaposi's Sarcoma, Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma-Light Chain Only
Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Biological: Filgrastim-sndz
Other: Laboratory Biomarker Analysis
Drug: Pomalidomide

First Posted Date: 2013-09-19

Last Posted Date: 2021-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 21

Registration Number: NCT01946152

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Dexamethasone
Drug: Daratumumab

First Posted Date: 2013-09-19

Last Posted Date: 2023-05-16

Lead Sponsor: Celgene

Target Recruit Count: 186

Registration Number: NCT01946477

Locations: 🇺🇸
Local Institution - 109, Los Angeles, California, United States
🇺🇸
Local Institution - 101, Hackensack, New Jersey, United States
🇺🇸
CR Wood Cancer Center, Glens Falls, New York, United States

and more 46 locations

Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males

Phase 1

Completed

Conditions: Clinical Pharmacology, Healthy Volunteer Study

Interventions: Drug: Pomalidomide

First Posted Date: 2013-04-19

Last Posted Date: 2019-11-12

Lead Sponsor: Celgene

Target Recruit Count: 32

Registration Number: NCT01835561

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
DaVita Clinical Research, Minneapolis, Minnesota, United States

Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis

Phase 1

Terminated

Conditions: Myeloma

Interventions: Drug: Pomalidomide
Drug: Melphalan
Drug: Dexamethasone
Behavioral: Questionnaires

First Posted Date: 2013-03-08

Last Posted Date: 2016-05-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01807286

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide

Phase 2

Completed

Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Drug: Dexamethasone
Drug: Lenalidomide
Drug: Pomalidomide

First Posted Date: 2013-02-18

Last Posted Date: 2018-08-21

Lead Sponsor: Mayo Clinic

Target Recruit Count: 9

Registration Number: NCT01794039

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bendamustine
Drug: Pomalidomide
Drug: Dexamethasone

First Posted Date: 2012-12-21

Last Posted Date: 2024-02-20

Lead Sponsor: Cristina Gasparetto

Target Recruit Count: 56

Registration Number: NCT01754402

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: POMALIDOMIDE
Drug: Dexamethasone

First Posted Date: 2012-12-10

Last Posted Date: 2015-12-04

Lead Sponsor: University Hospital, Lille

Target Recruit Count: 63

Registration Number: NCT01745640

Locations: 🇫🇷
CHRU-Hôpital Sud Amiens, Amiens, France
🇫🇷
Hôpital Haut-Leveque, PESSAC cedex, France
🇫🇷
Chru Lille, Lille, France

and more 17 locations

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Procedure: stem cell
Drug: Dexamethasone
Drug: Clarithromycin

First Posted Date: 2012-12-10

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 23

Registration Number: NCT01745588

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
North Shore LIJ, New Hyde Park, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 6 locations

Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2012-11-28

Last Posted Date: 2023-06-06

Lead Sponsor: Celgene

Target Recruit Count: 559

Registration Number: NCT01734928

Locations: 🇺🇸
Western Kentucky Hematology and Oncology Group, PSC, Paducah, Kentucky, United States
🇺🇸
Local Institution - 132, Bangor, Maine, United States
🇺🇸
St. Agnes - Medical Center, Baltimore, Maryland, United States

and more 318 locations

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Phase 1

Terminated

Conditions: Light Chain Deposition Disease
Primary Systemic Amyloidosis

Interventions: Drug: pomalidomide
Drug: bortezomib
Drug: dexamethasone
Other: Laboratory Biomarker Analysis

First Posted Date: 2012-11-19

Last Posted Date: 2023-05-09

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 18

Registration Number: NCT01728259

Locations: 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy